MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2023 Earnings Call November 9, 2023 8:30 AM ET
Company Participants
Zack Armen – Head, Investor Relations
Jennifer Buell - President and Chief Executive Officer
Marc Van Dijk - Chief Scientific Officer
Christine Klaskin – Principal Financial and Accounting Officer
Conference Call Participants
Emily Bodnar – H.C. Wainwright
Jack Allen – Baird
Brandon Carney - B. Riley
Matthew Phipps – William Blair
Operator
Good morning, and welcome to MiNK Therapeutics' Third Quarter 2023 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note this event is being recorded. If anyone has any objections, you may now disconnect at this time.
I will now turn the call over to Zack Armen, Head of Investor Relations at MiNK.
Zack Armen
Thank you, operator, and thank you all for joining us today. Today's call is being webcasted and will be available on our website for replay.
I'd like to remind you that this call will contain forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans as well as timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.
Joining me today on the call are Doctor Jennifer Buell, President and Chief Executive Officer; Doctor Marc Van Dijk, Chief Scientific Officer; and Christine Klaskin, Principal Financial and Accounting Officer.
Now, I'd like to turn the call over to Doctor Buell to highlight our progress in 2023 and plans for the year ahead.
Jennifer Buell
Thank you, Zack. It's a pleasure to have you all with us for MiNK’s third quarter earnings call 2023. I'm excited to report on the excellent headway we've made this quarter, particularly with our proprietary iNKT cell technology and pipeline programs. A pinnacle of this progress was presenting compelling new data and our flagship product, agenT-797 at the recent Society for Immunotherapy of Cancer or SITC annual meeting that took place last week.
To reiterate, 797 is an allogeneic iNKT cell therapy. It's distinguished by its scalability, robust immune modulatory properties and its administration without the need for toxic preconditioning regimens, a testament to the versatility and promise of these cells.
The findings we reported at SITC included first of kind data highlighting many of these unique benefits of iNKTs, particularly related to the lengthy persistence of the cells without lipo depletion or toxic preconditioning, Marc is going to tell you a bit more about that shortly.